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Background: The interest for gold nanorods in biomedical optics is driven by their intense absorbance of near
infrared light, their biocompatibility and their potential to reach tumors after systemic administration. Examples of
applications include the photoacoustic imaging and the photothermal ablation of cancer. In spite of great current
efforts, the selective delivery of gold nanorods to tumors through the bloodstream remains a formidable challenge.
Their bio-conjugation with targeting units, and in particular with antibodies, is perceived as a hopeful solution, but
the complexity of living organisms complicates the identification of possible obstacles along the way to tumors.
Results: Here, we present a new model of gold nanorods conjugated with anti-cancer antigen 125 (CA125) antibodies,
which exhibit high specificity for ovarian cancer cells. We implement a battery of tests in vitro, in order to simulate
major nuisances and predict the feasibility of these particles for intravenous injections. We show that parameters
like the competition of free CA125 in the bloodstream, which could saturate the probe before arriving at the tumors,
the matrix effect and the interference with erythrocytes and phagocytes are uncritical.
Conclusions: Although some deterioration is detectable, anti-CA125-conjugated gold nanorods retain their functional
features after interaction with blood tissue and so represent a powerful candidate to hit ovarian cancer cells.
Keywords: Gold nanorods, Cancer antigen 125, Active targeting, Competitive assay, Matrix effect, Blood compatibilityBackground
Cancer remains one of the leading causes of death. The
majority of patients suffering from cancer undergo inva-
sive treatments, such as surgery, radiation therapy and
chemotherapy. Radiation therapy is based on the use of
ionizing radiation to exterminate malignant cells via the
production of free radicals that damage cellular DNA
[1]. However, radio-toxicity to healthy tissue is a critical
factor, because ionizing radiation does not well discrim-
inate between malignant and normal cells [2,3]. Also
chemotherapeutics do not exclusively act on malignant
cells and exhibit side effects, mainly due to their poor
specificity [4]. In this context, the hope for more selective
alternatives has been revived by the advent of nanotech-
nology. In particular, gold nanoparticles (GNPs) have
received considerable attention. In addition to their good
biocompatibility, ease of preparation and stability, their* Correspondence: f.ratto@ifac.cnr.it
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unless otherwise stated.optical features are ideal for applications in biomedical
optics [5-10]. Their capacity to scatter and, more signifi-
cantly, to absorb light results from localized plasmonic
resonances [11-16].
Among the various shapes of GNPs, so-called gold
nanorods (GNRs) exhibit two plasmonic bands, i.e. a
weaker transversal band at ~ 520 nm, similar to that of
gold nanospheres, and a more intense longitudinal band
that moves from the visible to the near infrared (NIR)
domains, say from 600 to 1100 nm, with increasing their
aspect ratios [17-20]. Since tissue and skin compo-
nents do not significantly absorb NIR light, GNRs are
being proposed as contrast agents for many applications
in vivo [21-24].
While polyethylene glycol (PEG) imparts very low cel-
lular uptake [10], PEGylated GNRs tend to accumulate
into tumours after intravenous injection much more
than they do into normal tissue, because the vascular and
lymphatic networks of neoplastic tissue are abnormal.
This passive accumulation is known as the enhanced per-
meability and retention (EPR) effect. However, the fractiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Physical characterization. A) Representative TEM image
of CTAB-capped GNRs. B) Extinction spectra of CTAB-capped, PEGylated
and anti-CA125 GNRs, respectively from bottom to top. C) Zeta
potential and D) hydrodynamic diameter of CTAB-capped and
surface-modified GNRs (in H2O). n = 8 for the DLS measurements.
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10%, while their entrapment in vital organs, such as the
liver and the spleen, is substantial [25-29].
Various targeting units, such as antibodies [30-32], apta-
mers [33-35], peptides [36-38] and small molecules [39],
have been anchored to the surface of GNRs, in an attempt
to enhance their specificity for tumors. The interaction be-
tween these targeting units and their receptors on the
membranes of malignant cells activates pathways of active
uptake. The choice of molecular targets is critical. Popular
receptors, such as folate [40-42] and growth factor recep-
tors [43-45], are also found in most normal cells, and
cause some undeliberate uptake from these non-targeted
cells [46]. Nonspecific binding and specific binding to
non-targeted cells are common nuisances. Some authors
have proposed a dual-ligand approach to gain more speci-
ficity, especially when one of the molecular targets is ra-
ther unspecific [47-49]. In spite of all this effort, the
classification of problems and bottlenecks in the systemic
delivery of GNRs is hard, due to the extreme complexity
of the biological interface.
In this paper, we propose an analytical approach to
model in vitro some of the most critical issues that arise
from the interaction between GNRs and the bloodstream.
We focus on a single-ligand strategy, because the molecu-
lar target of our choice is Cancer Antigen 125 (CA125),
which is very specific for ovarian cancers. CA125, also
known as mucin 16, is the most reliable biomarker to
confirm the diagnosis and the management of ovarian
cancers, which is one of the most lethal gynaecological
malignancies, and is a large molecular weight transmem-
brane glycoprotein.
We describe the preparation and the application of
GNRs conjugated with anti-CA125 antibodies to detect
cells overexpressing CA125 and mediate their selective
photothermal ablation. The design of our probe starts
from the PEGylation of GNRs with heterobifunctional
PEG strands that confer biocompatibility, colloidal stabil-
ity [10] and an easy dock for anti-CA125 antibodies. We
place a special emphasis on the compatibility of these par-
ticles with intravenous injections, both in terms of their
performances of molecular recognition and their inter-
actions with erythrocytes and phagocytes. As for the
formers, the threat of biological environments providing
for competition and passivation is analyzed in solution by
complementary tests with a quantitative profile. The quali-
tative translation of these findings into the cellular arena
is confirmed by the specificity of anti-CA125 particles
for HeLa cells, which are CA125- positive, even after in-
cubation in biological fluids containing physiological levels
of this antigen. Moreover, we address their haemolytic ac-
tivity and their detection from macrophages, in an attempt
to mimic the interactions occurring in the blood, liver,
kidneys and spleen and exacerbating their blood clearanceand organ sequestration. In Additional file 1, we provide
evidence for the photothermal ablation of HeLa cells, thus
confirming the efficacy and selectivity of the treatment.
Our results demonstrate that anti-CA125 GNRs are non-
toxic, retain much of their ability of molecular recognition
after incubation in biological fluids, do not compromise the
erythrocytes and are not detected by the macrophages. For
these reasons, bio-conjugated GNRs represent a promising
platform for systemic delivery, in view of mini invasive im-
aging or therapeutic options based on concepts of photo-
thermal or photoacoustic conversion.
Results and discussion
CTAB-capped GNRs
As it is described in Methods, the preparation of our
particles began with the synthesis of GNRs stabilized by
hexadecyltrimethylammonium bromide (CTAB). TEM
images of CTAB-capped GNRs revealed average lengths
and widths of (43 ± 7) and (10 ± 3) nm, respectively (see
Figure 1A). These particles exhibited a longitudinal plas-
monic band around 800 nm (see Figure 1B).
Anti-CA125-conjugated GNRs
Due to the toxicity of CTAB, the initial coating was
substituted with a mixture of mono- and bi-functional
PEG strands (methoxylated PEG, or mPEG, and carboxyl-
ated PEG, or cPEG), which are nontoxic polyether com-
pounds in common use to improve the biocompatibility
Figure 2 Dot immunoassays. On the left, schematic representation
of a direct dot immunoassay performed using GNRs conjugated with
different antibodies and a photograph of nitrocellulose membranes after
incubation with various GNRs. Staining was only found in the presence
of specific antibodies. On the right, calibration curve of a CA125
sensor based on a dot immunoassay with a competitive format
and a photograph of a corresponding series of nitrocellulose
membranes at the end of the test.
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The carboxy-terminals of GNRs were conjugated with
antibodies anti-CA125, using the zero-length crosslin-
ker 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)
stabilized by N-hydroxysuccinimide (NHS) [52]. The reac-
tion mechanism between cPEG and antibodies anti-CA125
involves the activation of the carboxy moieties of cPEG
with EDC and NHS to form an unstable succinimide ester,
which is prone to react with the amino moieties of anti-
bodies to form a stable amide bond. As a confirmation of
their successive modifications, zeta potential and hydro-
dynamic size measurements were performed by dynamic
light scattering (DLS) on CTAB-capped GNRs, GNRs after
immobilization of mPEG and cPEG mixtures and GNRs
after conjugation with antibodies. The results are re-
ported in Figure 1C and D. Their zeta potentials revealed
the cationic [53], anionic and zwitteronic profiles of
CTAB-capped, PEGylated and anti-CA125 GNRs, respect-
ively. Likewise, their hydrodynamic radii underwent a
progressive increase, which may be expected from the
replacement of CTAB with PEG and then the addition of
antibodies. On the other hand, the optical extinction of
CTAB-capped, PEGylated and anti-CA125 GNRs showed
negligible variations (Figure 1B), thus suggesting that these
modifications preserved their plasmonic features.
Cytotoxicity
In order to gain some preliminary insight into the biocom-
patibility of anti-CA125 GNRs, cell viability was evaluated
in vitro in the presence of different doses of PEGylated
or anti-CA125 GNRs on HeLa cells (see Figure A1 in
Additional file 1). Anti-CA125 GNRs proved to be slightly
more cytotoxic than PEGylated GNRs, probably be-
cause of their active targeting or the effect of antibodies
per se. However, also anti-CA125 GNRs exerted little ef-
fect up to 100 μM Au.
Specificity and environmental competition
A direct dot immunoassay was performed using GNRs
with different modifications. The essential steps of this
test involved the immobilization of CA125 on nitrocellu-
lose membranes and its detection with anti-CA125 GNRs.
This assay was developed to mimic an in vitro scenario,
where CA125 is overexpressed on the surface of certain
malignant cells and anti-CA125 GNRs are brought into
contact with them. Staining occurred both with monoclo-
nal antibody (mAb) anti-CA125 GNRs and polyclonal
antibody (pAb) anti-CA125 GNRs, whereas GNRs conju-
gated with anti-rabbit immunoglobulins G (IgGs) did not
adhere to the membranes, thus demonstrating the active
role of the molecular recognition.
Furthermore, a dot immunoassay based on a competi-
tive scheme was developed using mAb anti-CA125 GNRs.
This assay was carried out to understand whether mAbanti-CA125 GNRs retain their ability to target their ana-
lyte even in the presence of free CA125. This circum-
stance mimics the in vivo conditions, where CA125 is
present in the bloodstream, besides that on the surface of
the malignant cells. In this case, the main steps of the
assay involved the immobilization of CA125 on nitro-
cellulose membranes (at one given concentration), the
incubation of a certain amount of anti-CA125 GNRs with
standard solutions of CA125 (at different concentrations)
and finally their interaction with the membranes. Staining
of the membranes was found to decrease with an increase
of free CA125 (Figure 2, on the right), consistent with
the trend of a competitive assay. A dose–response curve
for CA125 was retrieved by darkfield microscopy, from a
quantitative measurement of the intensity of optical
scattering from the particles (Figure 2, on the right). The
average coefficient of variation among the various concen-
trations of free CA125 was found to be 10%. The signal
began to decrease for CA125 concentrations higher
than ~ 50 ppm and nicely followed a logistic behavior.
The detection limit of this assay, i.e. the lowest concentra-
tion of free CA125 that was distinguishable from the
absence of the analyte beyond statistical fluctuations,
was ~ 90 ppm.
In practice, our immunoassay is unsuitable to discrimin-
ate healthy patients (CA125 in the range of 0 – 35 ppm)
from those with pathological levels of CA125 (≥ 35 ppm).
We note that the concentration of bio-conjugated GNRs
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injected in the bloodstream for tests in vivo (say at least
10 mg Au per Kg animal [27,54-56] or 50 g blood, i.e.
1 mM Au in the blood). Therefore, our findings imply that
the potential of anti-CA125 GNRs to target tumors is
retained even in a regime of pathological conditions. In
other words, our load of antibodies per particles is far
from saturation even in a pathological environment. This
result is not obvious, when it is considered that 400 μM Au
amount to ~ 2 nM particles and 35 ppm CA125 corresponds
to 40 – 150 nM CA125. At a glance, a lower limit for the
number of recognition sites per particle must be ~ 20. In
essence, anti-CA125 GNRs are good candidates to bind
ovarian cancer cells in vitro and in vivo.
Specificity and the matrix effect
Another source of criticalities is the matrix effect. This
effect was evaluated by a sandwich assay with an enzym-
atic label. A schematic representation of this assay is
shown in the left panel of Figure 3. The rate of appear-
ance of the enzymatic product (r) is proportional to the
number of fundamental events of molecular recognition.
Optical measurements in buffer solution and plasma
were recorded over time (0 – 60 minutes), in order
to quantify the enzymatic product. The kinetics of the
enzymatic reactions are reported in the right panel of
Figure 3. The slopes of the curves are similar in the cases
when the analyte was dissolved in a standard solution (r ~
(6.0 ± 0.6)*10−2 s−1) or contained in a complex matrix such
as plasma (r ~ (3.3 ± 0.3)*10−2 s−1). When CA125 was dis-
solved in the buffer solution, the kinetics was somewhat
higher, which may be ascribed to various factors, including
that the plasma could contain less than 30 ppm CA125 or
also suppress any aspecific signal, due to the passivation
given by the adsorption of plasmatic proteins. Anyway,
the comparison between these two kinetics suggests that
the matrix effect is not critical for these particles. The
standard solution of CA125 was also incubated withFigure 3 Sandwich assays. Left: schematic representation of the sandwic
enzymatic reactions when GNRs modified with specific antibodies were inc
(second steepest line) or when GNRs conjugated with aspecific antibodies (flaGNRs modified with anti-bovine IgGs and the sandwich
assay was run in order to gain an estimate of the extent of
aspecific signal. In the right panel of Figure 3, this kinetics
is compared with those obtained in the case of GNRs con-
jugated with specific antibodies. The incidence of aspecific
signal (r ~ (3 ± 3)*10−5 s−1) proved to be negligible with re-
spect to its specific counterpart.Specificity in vitro and the effect of biological fluids
The cellular uptake of GNRs was evaluated by darkfield
microscopy, silver staining and spectrophotometry. The re-
sults of these three methods agreed on the effect of the
surface modification on the uptake of GNRs by HeLa cells:
PEGylated GNRs exhibited the lowest uptake, while anti-
CA125 GNRs featured the highest uptake and specificity.Darkfield microscopy
The plasmonic features of the GNRs are useful to reveal
their cellular uptake by darkfield microscopy, which ex-
ploits the modulation of the optical scattering from a thin
sample. This method has become a popular approach to
identify GNRs in vitro [41,57], because of its noninvasive
profile and suitability for dynamic inspections of living
cells. After a preliminary characterization of the coeffi-
cients of optical scattering from the GNRs, the method
described in refs. [57,58] was used. For each field of view,
two darkfield images were acquired, spectrally filtered in
and off the principal plasmonic resonance of the GNRs
(780 nm high-pass and 510 nm bandpass filters). Then,
after background subtraction, a pixel by pixel operation
was performed to give a ratio image (R = I780 nm/I510 nm,
where I is the intensity at the named wavelength). This ra-
tio proved to be sensitive to the presence of GNRs.Three
samples of HeLa cells were prepared, i.e. with overnight
incubation of anti-CA125 GNRs or PEGylated GNRs and
a blank sample without particles. In order to keep a focus
on the cells, a mean value of R was calculated fromh assay with enzymatic label performed on GNRs. Right: kinetics of the
ubated with a standard solution of CA125 (steepest line), human plasma
ttest line) were incubated with the same standard solution of CA125.
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view and from various fields of view (≈ 10).
Results are plotted in Figure 4. The mean value of R as-
sociated with the anti-CA125 GNRs sample (red circles,
upper panel) was higher than those of the blank as well as
the PEGylated GNRs samples (black and blue circles, re-
spectively). A Student’s t-test was performed to qualify this
observation, with the following results: p < 10−5 for both
anti-CA125 GNRs – blank and anti-CA125 GNRs –
PEGylated GNRs pairs; p = 0.53 in the case of the blank –
PEGylated GNRs pair (~ 300 points for each sample).
These figures are consistent with an accumulation of anti-
CA125 GNRs and an absence of PEGylated GNRs.
Silver staining
Silver staining has become an option of choice for a quali-
tative assessment of the specificity of various gold nanopar-
ticles in vitro, because of its convenience and sensitivity
[36,43,59-65]. Here, metal particles nucleate the specific
deposition of silver from an appropriate silver salt (silver
acetate), in the presence of a suitable reducing agent
(hydroquinone). Silver-coated particles then catalyze more
silver deposition and so the silver grains grow in size and
eventually become visible under a standard microscope.
This principle was used to highlight the cellular uptake of
anti-CA125 GNRs.
HeLa and HCT 116 cells were treated with PEGylated
GNRs or anti-CA125 GNRs. Figure 5 shows that only the
specific GNRs/cell combination produced a significant pre-
cipitation of silver and thus a significant accumulation of
particles. For HCT 116 cells, no deposition of silver wasFigure 4 Darkfield microscopy analysis. Topmost panel: R value for each
area of the cell or cell cluster (black, red and blue for the blank, anti-CA125
the mean values of R for each of the three samples with their standard devobserved for either kind of GNRs. Instead, for HeLa cells,
a high precipitation of silver was only observed in the case
of anti-CA125 GNRs and this was well confined within
the cells. The comparison between anti-CA125 GNRs and
PEGylated GNRs was corroborated with a quantitative
spectrophotometric analysis [60], which gave a ratio be-
tween the extent of specific to aspecific uptake from HeLa
cells in the order of 6 ± 3 (see Figure A2 in Additional
file 1).
Finally, we verified the translation of our findings on the
interplay of environmental competition and matrix effect
in vitro. Particles were incubated with critical examples of
biological fluids (serum, plasma or ascitic fluid from mice
bearing ovarian cancers, at a representative rate of 400 μM
Au) for one hour and then left to interact with HeLa cells.
Even after this treatment, only anti-CA125 GNRs were
found to retain a significant uptake from HeLa cells, al-
though some attenuation of the pristine contrast with their
PEGylated counterpart is visible. This result confirms that
the interaction with free analyte in biological tissue does
not saturate the antibodies on the surface of the particles,
consistent with the outcome from our dot immunoassays.
In addition, the specificity of anti-CA125 GNRs without
and with preincubation in biological fluids was found
to correlate well with the efficiency of a hyperthermic
effect based on an optical treatment, as it is discussed
in Additional file 1 (see Figure A3).
Haemolysis and detection from macrophages
In order to complement our analysis on the suitability of
anti-CA125 GNRs for an intravenous administration, wecell or cell cluster for each of the three samples as a function of the
GNRs and PEGylated GNRs samples, respectively). Bottommost panel:
iations.
Figure 5 Silver enhancement. Evidence of targeting of CA125 via
silver staining, using HCT 116 and HeLa cells as negative and positive
models, respectively. Some samples of GNRs were preincubated with
serum, plasma and ascitic fluid before their administration into the
culture media.
Figure 6 Interactions with erythrocytes and macrophages.
Upper part: the degree of haemolysis produced by anti-CA125 GNRs
at various concentrations is reported and compared with that pro-
duced by PEGylated GNRs. Data are referred to positive controls that
were obtained by dosing ultrapure water to induce a complete
haemolysis. Lower part: the absence of silver deposition shows that
particles are not internalized by macrophages.
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cubated with a positive control (ultrapure water), a nega-
tive control (normal saline) or various concentrations of
anti-CA125 GNRs or PEGylated GNRs. According to
the topmost panel of Figure 6, anti-CA125 GNRs exhib-
ited the same behavior as PEGylated GNRs and both
types of particles displayed no haemolytic activity, even
at their highest concentrations. Data are referred to posi-
tive controls obtained by dosing ultrapure water to in-
duce a complete haemolysis.
Moreover, we implemented a phagocytosis assay, because
this parameter may impair the ability of anti-CA125 GNRs
to remain in the bloodstream by their sequestration from
phagocytes. The amount of gold internalized by macro-
phages exposed to anti-CA125 GNRs or PEGylated GNRs
at a concentration of 100 μM Au was probed by silver
staining after an overnight incubation. Here, 12 – 18 hours
are regarded as an upper limit for the persistence of bio-
conjugated GNRs in the bloodstream [44]. As shown in
the bottommost panel of Figure 6, on visual inspection, noprecipitation of silver was found for the PEGylated GNRs
sample, as it is expected from the literature [10,28], but
also for the anti-CA125 GNRs sample. Therefore, the
addition of anti-CA125 antibodies did not jeopardize the
stealth profile imparted by the PEG portion.
Conclusions
In conclusion, we have presented a model of anti-CA125-
conjugated gold nanorods that are intended to target
ovarian cancer cells after intravenous injection. We have
combined a battery of tests to understand their specificity
for surfaces and cells overexpressing CA125, as well as
possible issues that may arise from their interface with a
bloodstream, both in terms of their performances of mo-
lecular recognition and their compatibility with erythro-
cytes and phagocytes. We have found that both the
competition from free CA125 in biological fluids and the
matrix effect affected the ability of our particles to detect
their biochemical target to a moderate extent. This modu-
lation was analytically quantified in solution and qualita-
tively confirmed in cells. In addition, our particles were not
harmful to erythrocytes and did not suffer from massive
phagocytosis and sequestration from macrophages, such as
those residing in the liver, kidneys and spleen.
With these premises, our particles are a meaningful
candidate for future investigations with animal tissue
ex vivo and in vivo. While this analysis does not intend
to replace animal testing, we are confident that our ap-
proach may inspire additional efforts to enhance the pre-
liminary screening of functional particles that are directed
to systemic administration. Our future work will aim to re-
fine the dependability of our models and the quantitative
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ticles and their biological targets in the presence of a circu-
latory system.
Methods
Materials
HAuCl4 (hydrogen tetrachloroaurate (III) hydrate), CTAB
(hexadecyltrimethylammonium bromide), NaBH4 (sodium
borohydride), ascorbic acid, silver nitrate, NHS (N-hydro-
xysuccinimide), EDC (1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide), polysorbate 20, paraformaldehyde, sil-
ver acetate, hydroquinone, trypsin, trypan blue, anti-rabbit
IgG labelled with alkaline phosphatase, 4-nitrophenyl
phosphate bis(cyclohexylammonium) salt, milk powder,
human serum, human plasma and MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay kit as
well as all chemicals for the various buffer solutions were
purchased from Sigma Aldrich. Monoclonal mouse anti-
body anti-CA125 (mAb anti-CA125), polyclonal rabbit
antibody anti-CA125 (pAb anti-CA125) and CA125
partial recombinant protein were purchased from Novus
Biologicals. Alpha-methoxy-omega-mercapto-poly(ethylene
glycol) (mPEG-SH) and alpha-carboxy-omega-mercapto-
poly(ethylene glycol) (cPEG-SH), Mw ≈ 5000 gmol
−1, were
provided by Iris Biotech. All cell culture media, fetal calf
serum and antibiotics (penicillin and streptomycin) were
purchased from Gibco. All chemicals were of analytical
grade. Nitrocellulose membranes with pore size of 0.45 μm
were purchased from Whatman.
Cell lines and culture conditions
Human colon colorectal carcinoma cells (HCT 116) (nega-
tive line, i.e. not expressing CA125), human cervix carcin-
oma cells (HeLa) (positive line, i.e. overexpressing CA125)
and murine macrophages were used. All cell lines were
maintained in Dulbecco Modified Eagle Medium (DMEM)
supplemented with fetal bovine serum, 100 units/mL peni-
cillin, and 100 μg/mL streptomycin and kept under stand-
ard culture conditions (37°C, 5% CO2, 95% air and 100%
relative humidity).
Instrumentation
Optical spectra of aqueous suspensions of GNRs were
measured by a UV-NIR spectrophotometer (V-560, Jasco,
Japan). Their zeta potential and hydrodynamic size were
characterized by Dynamic Light Scattering (DLS, Zetasizer
Nano-ZS90, Malvern Instruments, UK). Imaging was
performed by Transmission Electron Microscopy (TEM,
CM12, Philips, the Netherlands) or optical microscopy
operated in darkfield or standard conditions. For TEM,
GNRs were left to dry on carbon-coated films and imaged
at 100 kV. The darkfield microscope consisted of a Nikon
(Japan) Eclipse TE-2000 platform equipped with a Nikon
darkfield condenser (immersion oil, min NA= 1.2, maxNA = 1.4), a Nikon 10 × objective (NA = 0.3), a set of
optical filters (510 nm, 40 nm FWHM passband filter
XF3043, Omega Optical, USA and 780 nm highpass filter
OG780, Schott AG, Germany) and a CCD camera (Cool-
snap-HQ2, Roper Scientific, USA). Cells were also observed
with a Leica (Germany) DMI3000B inverted microscope.
The optical excitation described in Additional file 1 was
performed with a low power 810 nm diode laser (Weld
800, El.En., Italy).
Synthesis of GNRs
CTAB-capped GNRs were synthesized by the autocata-
lytic reduction of HAuCl4 with ascorbic acid, according
to the method proposed by Nikoobakht et al. [66], with
the variant and overgrowth by Ratto et al. [18].
PEGylation of GNRs
After purification by two cycles of centrifugation and de-
cantation with a dead volume ratio of ~ 1/200, GNRs
were transferred at a concentration of 1.6 mM Au into a
100 mM acetate buffer at pH 5 containing 500 μM cetri-
monium bromide and 5 μM cPEG-SH. This suspension
was left to react at 37°C for 30 minutes and then 50 μM
mPEG-SH was added and kept at rest for another 90 mi-
nutes. After purification, GNRs were transferred at a
concentration of 1.6 mM Au into a 10 mM MES buffer
at pH 6 containing 120 mM NaCl and 0.005% (v/v) poly-
sorbate 20. The Mw of PEG of ≈ 5000 gmol
−1 was chosen
to provide for high colloidal stability, low aspecific inter-
actions with cells [10] and so the perspective to take full
advantage of the EPR effect [67].
Preparation of anti-CA125-conjugated GNRs
An equal volume of a solution containing 12 mM NHS
and 48 mM EDC was added to a suspension of GNRs at
a concentration of 1.6 mM Au in 10 mM MES buffer at
pH 6. After 15 minutes of activation, this suspension was
incubated with a double volume of 20 ppm Ab anti-CA125
in MES buffer at pH 6 containing 120 mM NaCl and
0.005% (v/v) polysorbate 20. After one hour, 10 mM 2-
methoxyethylamine was dosed for 30 minutes, in order to
block any unreacted succinimide ester. After purification
by two cycles of centrifugation and decantation with a
dead volume ratio of ~ 1/200, GNRs were transferred at a
concentration of 4.0 mM Au into sterile PBS.
Dot immunoassay
Dot immunoassays were performed using 0.45 μm pore
size nitrocellulose membranes. In a typical protocol of a
direct assay, 1 μL of 1000 ppm CA125 partial recombin-
ant protein in carbonate buffer at pH 9.6 was spotted
onto a membrane. Then, the spot was left to dry in an
oven at 37°C for 20 minutes. Nonspecific binding was
inhibited by incubation of the membrane for 40 minutes
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3% (w/v) milk powder. Then, the membrane was incu-
bated for one hour at room temperature and under gen-
tle stirring with 500 μL of a suspension of 400 μM Au
mAb anti-CA125 GNRs, pAb anti-CA125 GNRs or anti-
rabbit IgG GNRs. Finally, the membrane was washed
twice with a PBS buffer containing 0.1% (v/v) polysor-
bate 20 and left to dry at room temperature.
For a competitive assay, nitrocellulose membranes were
spotted with CA125 and blocked, as in the case of a direct
assay. Meanwhile, 400 μM Au mAb anti-CA125 GNRs
were incubated for one hour with standard solutions
containing variable concentrations of CA125, in the range
0 – 5000 ppm. After purification, GNRs were resuspended
at a concentration of 400 μM Au in 1 mL of PBS buffer
and incubated with the membranes for one hour at
room temperature and under gentle stirring. Finally, the
membranes were rinsed with abundant PBS buffer con-
taining 0.1% (v/v) polysorbate 20 and left to dry at room
temperature. The readout was devised as a quantitative
light scattering measurement by darkfield microscopy,
which reflects the amount of GNRs bound to the
membranes.
Sandwich assay
50 μL of mAb anti-CA125 GNRs at a concentration of
4.0 mM Au in PBS buffer were added to 450 μL of PBS
buffer supplemented with 30 ppm CA125 or 450 μL of
human serum or plasma containing their physiological
level of CA125. After one hour of incubation at 37°C,
GNRs were purified and resuspended at a concentration
of 4.0 mM Au in 50 μL of PBS buffer and incubated for
one hour at 37°C with 450 μL of PBS buffer containing
20 ppm pAb anti-CA125 that had formerly been left to
react for 30 minutes with anti-rabbit IgG labelled with
alkaline phosphatase (1/20000 of its stock solution).
After purification, 50 μL of GNRs at a concentration of
4.0 mM Au were transferred into 450 μL of 2.4 mM 4-
nitrophenyl phosphate bis(cyclohexylammonium) salt in
DEA buffer. The alkaline phosphatase enzyme catalyzed
the formation of a soluble end product that was bright
yellow. This reaction was monitored with a spectropho-
tometer at 405 nm.
Measurement of cellular uptake
Cellular uptake of the mAb anti-CA125 GNRs was eval-
uated using three different techniques, i.e. darkfield mi-
croscopy, silver staining and spectrophotometry. HeLa
and HCT 116 cells were seeded and allowed to grow for
24 hours in 24-well culture plates or on glass coverslips.
Cells were then treated overnight with mPEG GNRs
(non-targeted particles) and mAb anti-CA125 GNRs
(targeted particles) at a concentration of 100 μM Au in
culture medium. Untreated cells served as a backgroundcontrol. Alternatively, some aliquots of mPEG GNRs and
mAb anti-CA125 GNRs at a concentration of 400 μM Au
were exposed to human serum, plasma or murine ascitic
fluid for one hour, centrifuged and decanted, prior to their
incubation with the cells at a concentration of 100 μM Au
in culture medium. The day after, cells were washed with
abundant PBS in order to remove all unbound GNRs.
For darkfield microscopy and silver staining, cells were
fixed in a solution of 3.6% paraformaldehyde in PBS buf-
fer for 5 minutes and washed with PBS buffer to remove
the excess of reagents. For a qualitative inspection by sil-
ver staining, samples were incubated for 5 minutes with
23 mM hydroquinone in citrate buffer at pH 3.8 and
then for 4 – 18 minutes with the same solution supple-
mented with 6 mM silver acetate. All solutions were as
fresh as possible. Samples were observed with a standard
microscope. For a quantitative optical analysis, cells were
counted, centrifuged and suspended in 120 μL of DI
water, before inspection with a spectrophotometer (see
Figure A2 in Additional file 1).
Measurement of interactions with erythrocytes and
macrophages
For the evaluation of haemolysis, informed signed con-
sent was obtained and human whole blood was collected
from healthy volunteers. Test tubes containing 1.8 mg/mL
EDTA were used to collect the whole blood. Samples were
centrifuged at 3000 rpm for 20 minutes and the buffy coat
was collected and washed with normal saline. 100 μl of
samples diluted with normal saline to a 50% hematocrit
were added to 3 mL of normal saline (as a negative con-
trol), ultrapure water (as a positive control) and suspen-
sions of anti-CA125 GNRs in PBS buffer at different
concentrations. All samples were incubated at 37°C for
one hour and haemolysis was stopped by the addition of
50 μl of 2.5% glutaraldehyde, prior to centrifugation at
3000 rpm for 15 minutes. Supernatants were collected in
96-well microplates. Their absorbance was measured at
405 nm by an automated plate reader.
The uptake of anti-CA125 GNRs from macrophages
was visualized by silver staining.
Additional file
Additional file 1: Cytotoxicity, quantitative measurement of cellular
uptake, optical hyperthermia in vitro. This file contains additional
information on the biological profiles and functional properties of
anti-CA125 GNRs [68-71].
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